MedTrace Logo

Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by ENDS Consumers

NCT04620616 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-01-19

No results posted yet for this study

Summary

This study is being conducted to evaluate nicotine uptake, the potential abuse liability, and puffing topography associated with the use of an electronic nicotine delivery system (ENDS) with tobacco- and menthol-flavored e-liquids in current ENDS consumers.

Conditions

  • Electronic Cigarette Use

Interventions

OTHER

RELX ENDS Tobacco Flavor

Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

OTHER

RELX ENDS Menthol Flavor

Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions

OTHER

Subject Usual Brand ENDS

Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions

Sponsors & Collaborators

  • Cheerain HK Limited

    lead INDUSTRY

Principal Investigators

  • Donald Graff, PharmD · Sponsor Representative

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
22 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-11
Primary Completion
2021-01-04
Completion
2021-01-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04620616 on ClinicalTrials.gov